Journal of medicinal food最新文献

Disturbances of the intestinal barrier enabling bacterial translocation exacerbate alcoholic liver disease (ALD). Lactobacillus rhamnosus GG (LGG) has been shown to exert beneficial effects in gut dysbiosis and chronic liver disease. The current study assessed the combined effects of LGG and metformin, which play roles in anti-inflammatory and immunoregulatory processes, in alcohol-induced liver disease mice. A diet comprising 5% alcohol for 4 weeks was employed to develop an alcohol-induced liver injury model. Mice were orally administered LGG, metformin, or their combination on alternate days. Tight junction (TJ) proteins, gut microbiome composition, inflammatory cytokines, Jun N-terminal kinase (JNK), and p38 signals were assessed. When compared with treatment with LGG or metformin alone, combined LGG and metformin treatment substantially lowered the symptoms of inflammation, steatosis, and elevated liver enzymes caused by alcohol administration. Combination treatment significantly improved intestinal microecology, evidenced by the recovery of intestinal flora, TJ proteins, and intestinal villi. Combination treatment reduced hepatic inflammation by blocking p38 and JNK phosphorylation. The combination of LGG and metformin corrected immune-response dysregulation and improved ALD by enhancing the intestinal microbiome, restoring mucosal barrier integrity, modulating immune function, and decreasing liver injury. These results provide information for the development of intestinal microbiota-based preventive and therapeutic agents against ALD.

Recent studies show that inorganic arsenic (As) exerts a toxic effect on the intestinal epithelium, causing a significant increase in its permeability. This disruption of the epithelial barrier may favor the entry of contaminants or toxins into the systemic circulation, thus causing toxicity not only at the intestinal level but possibly also at the systemic level. The present study conducts an in vitro evaluation of the protective effect of various dietary supplements and plant extracts against the intestinal toxicity of inorganic As. Some of these compounds were found to exert a protective effect. A significant decrease was observed in intracellular reactive oxygen/nitrogen species (10-31%), as well as a lower secretion of the pro-inflammatory cytokine IL-8 (25-41%) in the intestinal monolayers treated with the supplements and extracts, compared with those exposed only to As(III). The most effective supplements (glutathione/cysteine/vitamin C and lipoic acid) also normalized the distribution of tight junction protein zonula occludens-1, with partial restoration of the paracellular permeability and cell regeneration capacity of the intestinal epithelial cells. The results obtained show that dietary supplements and plant extracts can reduce the intestinal barrier disruption caused by inorganic As, and this may have a positive impact at both local and systemic levels.

Black cumin (Nigella sativa L.) (family Ranunculaceae) is a largely utilized therapeutic herb worldwide. This comprehensive review discusses the pharmacological benefits of black cumin seed oil, focusing on its bioactive component thymoquinone (TQ). The review is structured as follows: First, we examine the antimicrobial properties of black cumin oil, followed by an analysis of its antioxidant capabilities. Finally, we explore its therapeutic potential, particularly in neurodegenerative diseases and COVID-19. Phytochemicals from N. sativa have exhibited potential for developing novel preventive and therapeutic strategies against jaundice, gastrointestinal disorders, skin diseases, anorexia, conjunctivitis, dyspepsia, intrinsic hemorrhage, amenorrhea, paralysis, anorexia, rheumatism, diabetes, hypertension, fever, influenza, eczema, asthma, cough, bronchitis, and headache. The broader spectrum of application for N. sativa and its essential bioactives have certainly enhanced the commercial value of this seed oil. TQ, a major constituent of black cumin seed oil, has numerous beneficial properties. Researchers have extensively studied black cumin seed oil and its major component, TQ. These studies have revealed a wide range of pharmacological properties, including anticancer, immunomodulatory, analgesic, antimicrobial, antidiabetic, and anti-inflammatory effects. Additionally, TQ has shown neuroprotective, spasmolytic, bronchodilatory, hepatoprotective, renoprotective, gastroprotective, and antioxidant activities.

The effect of the aqueous extract of Azadirachta indica (AAI) on gentamicin (GEN)-induced kidney injury was investigated. The study involves 20 adult male Wistar rats (housed in four separate plastic cages) such that graded dosages of AAI were administered to the experimental group for 14 days per oral (PO) before exposure to GEN toxicity (100 mg/kg) for 1 week. At the end of the study, comparisons of some markers of renal functions, antioxidant status, and inflammatory and apoptotic markers were made between the control, GEN, and AAI-pretreated groups at P < .05. The result showed that GEN treatment caused a significant increase (P < .05) in body weight, kidney weight, urea, bilirubin, kidney injury molecule 1 (KIM 1), cystatin C, malondialdehyde (MDA), reduced glutathione (GSH), tumor necrotic factor alpha (TNF-α), interleukin-1 (IL-2), caspase-3, and B-cell lymphoma-2 associated X (BAX) as well as a significant decrease (P < .05) in superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (Gpx), and B-cell lymphoma (BCL)-2 level. Pre-treatment with graded doses of AAI caused a significant increase in urea, CAT, and GPx as well as a significant decrease (P < .05) in kidney weight, bilirubin, KIM 1, cystatin C, MDA, GSH, SOD, TNF-α, IL-2, caspase-3, BAX, and BCL-2. There was an appreciable difference in the kidney histology of the AAI pre-treated groups compared with the GEN. Hence, the extract has prophylactic potential in managing GEN-induced nephrotoxicity by decreasing the markers of renal function and inflammation and downregulating the markers of apoptosis.

Photoprotective effects of various nutritional components and supplements have been demonstrated in animal and in vitro studies. The objective of this systematic review is to assess the photoprotective effects of various dietary supplements. A systematic review of studies assessing dietary supplements on photoprotective outcomes was performed. Human studies were retrieved from PubMed, Embase, and Cochrane in February 2023. Supplement keywords included "dietary supplements," "vitamins," "minerals," "carotenoids," "lutein," "isoflavones," "polyphenols," "Polypodium leucotomos," "heliocare," "herbal medicine," "probiotics," "prebiotics," "astaxanthin," "rosmarinic acid," "botanical," and "herb," and outcome keywords included "photoprotection," "ultraviolet rays," UVA," "UVB," and "blue light." A total of 47 studies were included in the systematic review. Studied supplements included carotenoids, polyphenols, Polypodium leucotomos (PL), melon concentrate, vitamins, coenzyme Q, squalene, and omega-3 and omega-6 fatty acids. Some studies evaluated mixed supplementation and incorporated other active ingredients such as selenium and probiotics. The greatest evidence of photoprotection exists for polyphenols, carotenoid-based, and PL supplementation. While flavanol supplementation exhibited dose-dependency, dose-dependency could not be consistently demonstrated for polyphenol supplementation. The weakest evidence exists for photoprotective effects of isolated vitamin or coenzyme Q supplementation. Dietary supplements may promote enhanced photoprotection, although current evidence is limited by small sample size and short duration. Supplementation with photoprotective active ingredients may be especially favorable for individuals with predisposed ultraviolet sensitivity, such as those with polymorphic light eruption. Future research is necessary to determine optimal dosing and supplementation duration for intended photoprotective outcomes.

Ziziphus lotus L., or "Sedra" in North Africa, is a wild jujube from the Rhamnaceae family. Its fruit, "Nbeg," is used in traditional medicine to treat various ailments, such as tuberculosis, bronchitis, liver disorders, and gastrointestinal issues. This mini review highlights the main nutritional and medicinal properties of Nbeg and its potential application in human health and nutrition. Current scientific articles have recommended the use of Z. lotus-derived compounds to generate novel treatments due to their diverse biological functions (anti-ulcer, wound healing, litholytic, and antispasmodic effects). Z. lotus appears to be a good source for antioxidant compounds (phenolics and flavonoids, which are a diverse group of natural compounds belonging to the polyphenol family) and nutritional molecules (carbohydrates, amino acids, triacylglycerol, proteins, sterols, fibers, vitamins, lipids, and minerals), which made it a viable option for human nutrition and health promotion.

Vitamin B₅, or pantothenate, forms the molecular "backbone" of coenzyme A (CoA), which is essential for more than a hundred biochemical reactions in humans. Genetic defects that disrupt the CoA pathway cause severe degenerative disorders that may be amenable to treatment with compounds that can bypass the metabolic block. The pantothenate metabolite, 4'-phosphopantetheine (4'PPT), can serve as an alternative substrate for cellular CoA synthesis and may therefore be an essential nutrient in managing disorders where pantothenate cannot meet all metabolic requirements. 4'PPT is present in foods in low quantities, but the safety of the compound administered at higher doses than available in a normal diet has never been evaluated. In this study, we examined the effects of short-term high-dose oral 4'PPT in wild-type mice. Three doses of up to 250 mg/kg body weight were administered orally each day for 15 days. Daily body weights and cage-side general health and neurotoxicity screens were obtained. These were followed by terminal necropsy and histological analysis of major organs and tissues, including liver, kidney, heart, brain, stomach, muscle, spleen, and testis/ovary. No significant adverse effects were found in any of the analyses. We conclude that even at high doses, 4'PPT, like pantothenate, causes no observed adverse effects.

Respiratory tract diseases (RTDs) cause airflow limitations and impaired respiratory function, primarily due to pulmonary inflammation and immune dysfunction. Chrysanthemum zawadskii var. latilobum Kitamur and Platycodon grandifloras (CP) are traditional herbs known for their anti-inflammatory and immune-enhancing properties. This study investigates the anti-inflammatory and immune-enhancing effects of a combined extract of CP in vivo. CP was prepared by mixing equal volumes of Chrysanthemum zawadskii extract (CE) and Platycodon grandifloras extract (PE) at the same concentration. The anti-inflammatory effects of CP were evaluated using a lipopolysaccharide (LPS)-induced inflammation model in BALB/c mice. The immune-enhancing effects were assessed using a cyclophosphamide (CYP)-induced immunosuppression model. Protein and mRNA expressions of inflammatory and immune markers were analyzed through Western blotting and quantitative real-time PCR. CP significantly reduced LPS-induced pulmonary inflammation by decreasing interleukin (IL)-1β and cyclooxygenase-2 expression in lung tissues. In the CYP-induced model, CP treatment restored spleen and thymus weights, reversed reductions in immune cell counts, and increased TNF-α and IL-2 mRNA expression in the spleen. In conclusion, CP inhibits pulmonary inflammation by suppressing inflammatory mediators and enhances immune function by increasing immune-related indicators. This suggests that CP may have potential therapeutic applications for treating respiratory inflammation and related diseases.

Millions of men and women suffer from alopecia, especially androgenic alopecia (AGA), which is considered the most common form of hair loss. The available treatments for hair loss include multiple approaches, with the most popular being synthetic drugs including minoxidil and finasteride, in addition to natural products. However, synthetic drugs have shown many undesirable side effects, on the contrary, the specifications of the commonly used natural drugs have not been reported in most of the previous studies, despite the high market preference for them. One of these natural drugs is soybean (Glycine max), an economically important bean that has been reported in several studies to effectively prevent hair loss in humans and is widely used in many products treating alopecia. However, no reports were traced on the specification and standardization of the used soybean extract, which may lead to unreproducible results. Thus, in this study, we investigated the effects of different concentrations; 1%, 3%, and 5% (v/v) of a specified soybean extract (SSE) in coconut oil, using a testosterone-induced model of alopecia in adult male Wistar rats in comparison with a 2% finasteride solution. Visual and microscopical evaluations of follicular diameter, length, and density were performed. The data showed that 5% of SSE exhibited the highest activity with results comparable to standard 2% finasteride for hair diameter, length, and density, which could be attributed to the extract's isoflavone content. Genistin and diadzin isoflavones were isolated from the ethyl acetate fraction of the SSE. The total extract was standardized using high-performance liquid chromatography using genistin as a marker and showed a content of 6.2 µg/mL. Accordingly, the formulated 3% and 5% SSEs (containing 0.186 and 0.31 µg/mL of genistin, respectively) could be considered as a promising natural treatment for AGA.

This clinical study aimed to assess the effectiveness and safety of Vuong Hoat (VH) natural health supplement for reducing the negative impact of low back pain, improving the quality of life, and enhancing functional activities in patients with lumbar degenerative disc disease (LDD). The open-label, randomized, controlled clinical trial involved 60 patients suffering from low back pain caused by LDD. The participants were randomly assigned to either a study group (SG) comprising 30 subjects or a control group (CG) comprising 30 subjects. Patients in the CG received treatment with electro-acupuncture, while those in the SG were administered VH in conjunction with the same electro-acupuncture protocol for 28 days. The clinical progression and tolerability of both groups were compared based on seven objective measurements: visual analog scale index, Schober test, fingertip-to-floor distance, spinal flexion, spinal extension, spinal tilt, and spinal rotation. After 14 days of treatment, the SG showed a significant improvement in overall outcomes compared to the CG. Specifically, 43.3% of SG patients achieved very good results, 53.3% had good results, and 3.4% had moderate results, whereas corresponding figures for the CG were 6.7%, 76.7%, and 16.6%, respectively (P < .05). After 28 days of treatment, both groups demonstrated a shift toward very good results, with the SG continuing to show better outcomes than the CG (P < .05). In the SG, the very good results increased to 76.7%, good results decreased to 20%, and moderate results were 3.3%. On the other hand, the CG had 46.7% very good results, 43.3% good results, and 10% moderate results. Notably, no side effects were reported from the VH treatments during the study. The findings of this study indicate that VH health supplement is a safe and effective approach for managing low back pain and limited spinal movement in patients with LDD.